Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)

Advanced Non-squamous NSCLC Clinical Trial

Official title:

An Open, Single-arm, Multi-center Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03778853
• Other study ID #: 20180049
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: January 2019
• Est. completion date: December 2019

Study information

• Verified date: December 2018
• Source: LanZhou University
• Contact: da zhao, professor
• Phone: 0086-13369287188
• Email: Ydfyzhaohon[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor celltebiz related kinase -c-Kit kinase. In the phase III study, Patients who failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance were treated with anlotinib (12mg, po. qd. on day 1to14 of a 21-day cycle) or placebo, the anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group PFS and OS were 1.4 months and 6.3 months.

Description:

It is an open, single-arm, multi-center clinical trial conducted in China, and plan to Recruiting 72 patients in the elderly without systemic chemotherapy. Patents receive 12mg anlotinib orally daily on day 1to 14 of a 21-day cycle until progression of disease, assess safety and efficacy of the drug.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 72
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

• Signed and dated informed consent

• Age:=70

• Subjects with histologically or cytologically confirmed locally advanced and/or advanced NSCLC

• at least two systematic chemotherapy with upwards of 1-line treatments or cannot suffer

• The negative patients in EGFR&ALK can participate or who positive in EGFR&ALK, have or have not drug tolerance after the treatment with relative targeted drugs

• Subjects with at least one measurable lesion as defined by RECIST (version 1.1)

• Expected Survival Time: Over 3 months

• ECOG PS:0-1

• main organs function is normal

Exclusion Criteria:

• 1.Small Cell Lung Cancer (including small cell cancer and other kinds of cancer mixed with non-small cell cancer)

• lung squamous carcinoma

• Other active malignancies requiring treatment

• History of malignancy

• Have got non remissive toxic reactions derived from previous therapies, which is over level 1 in CTC AE (4.0), alopecia NOT included

• Abnormal coagulation (INR>1.5 or PT>ULN+4s or APTT >1.5 ULN); Patients with any physical signs of bleeding diathesis or receiving thrombolysis and anticoagulation

• take major surgical treatments or have serious trauma before grouping, or the impact of surgery or trauma has been eliminated for less than 14 days

• Patients with active or unable to control serious infections

• Patients with Grade II or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QTc male = 450 ms, female = 470 ms) ; Patients with grade III to IV cardiac insufficiency, or left ventricular ejection fraction (LVEF) <50% (NYHA Classification)

• Patients with non-healing wounds or fractures

• with kinds of factors which affect oral medicine (e.g. failing to swallow, gastrointestinal tract getting resected, chronic diarrhea and ileus).

• get arterial/venous thrombosis within 12 months, such as cerebrovascular accidents (including temporary ischemic stoke), deevenous thrombosis, and pulmonary embolism

• Patients with cirrhosis, decompensated liver disease, or active hepatitis Have suffered from hemorrhagic disease or coagulation dysfunction

• diagnosed with disease which will severely endanger the security of patients or influence the completion of this research

Related Conditions & MeSH terms

• Advanced Non-squamous NSCLC

Intervention

Drug:
• Anlotinib Hydrochloride
Anlotinib Hydrochloride ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage. Other Name: AL3818

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
LanZhou University	General Hospital of Ningxia Medical University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS	Progress free survival (PFS)	Time Frame: each 42 days up to PD or death(up to 24 months)
Secondary	OS	Overall Survival (OS)	From randomization until death (up to 24 months)
Secondary	DCR	Disease Control Rate (DCR)	each 42 days up to intolerance the toxicity or PD (up to 24 months)
Secondary	ORR	Objective Response Rate (ORR)	each 42 days up to intolerance the toxicity or PD (up to 24 months)
Secondary	Number of Participants with Adverse Events as a Measure of Safety and Tolerability	Number of Participants with Adverse Events as a Measure of Safety and Tolerability	Until 30 day safety follow-up visit
Secondary	EORTC QLQ-C30	use EORTC QLQ-C30(version 3) questionnaire to evaluate the quality of life	each 42 days up to intolerance the toxicity or PD (up to 24 months)